Evidence map›Paper›PMID 32749781›Full record

ArticleActa ophthalmologica2021

Multidisciplinary management of auto-immune ocular diseases in adult patients by ophthalmologists and rheumatologists.

Rianne Elise Van Bentum, Jesse M Van den Berg, Sanne E Wolf, Joyce Van der Bijl, H Stevie Tan, Frank D Verbraak, Irene E van der Horst-Bruinsma

Open access · hybridAbstract read
In one paragraph

Article in Acta ophthalmologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rianne Elise Van BentumDepartments of Rheumatology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-0075-4235
Jesse M Van den BergDepartments of Rheumatology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-3270-6641
Sanne E WolfDepartments of Ophthalmology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0001-8560-2825
Joyce Van der BijlDepartments of Rheumatology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-1296-0151
H Stevie TanDepartments of Ophthalmology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0001-8368-1048
Frank D VerbraakDepartments of Ophthalmology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0001-7560-1423
Irene E van der Horst-BruinsmaDepartments of Rheumatology, Amsterdam University Medical Center, Location VU Medical Center, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-8086-9915
Amsterdam University Medical Centers · NLBergman Clinics · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeManagement of chronic vision threatening auto-immune ocular diseases (AIOD, e.g. uveitis, scleritis) can be challenging. Guidelines recommend a multidisciplinary approach (MDA) with ophthalmologists and rheumatologists, to enhance the recognition of systemic diseases and guide the use of immunosuppressives. However, the indications and results of such an approach have not yet been studied.

methodsA monocentre, retrospective chart review of all patients treated in a MDA between ophthalmologists and rheumatologists, in a Dutch tertiary center. The collaboration was twofold: a combined multidisciplinary team meeting every 2 weeks, and an ophthalmology-dedicated rheumatology outpatient clinic. Primary endpoints of this descriptive study were as follows: indications for MDA, new diagnoses of systemic auto-immune diseases and changes in systemic immunosuppression and prednisone dosages.

resultsIn total, 157 adults (mean age 46 years, 57% female, median disease duration 19 months) were included, mainly with uveitis (74%) and scleritis (12%). Multidisciplinary approach (MDA)-indications included diagnostic workup (32%), treatment support (44%), diagnostic-and-treatment support (10%) and side effects (8%). A systemic disease was newly diagnosed in eight and already present in 34 patients. At baseline, 54 patients used oral prednisone at >7.5 mg/day. Non-corticoid immunosuppressives, mostly methotrexate, were started in 41% of the patients. During follow-up, systemic prednisone was lowered to ≤7.5 mg/day in 68% of the patients.

conclusionThis evaluation of an MDA-programme in the management of AIOD demonstrated its added value. Mainly, it addressed the high demand for support in managing systemic immunosuppression, resulting in significant corticosteroid tapering. In addition, it resulted in the recognition of underlying systemic diseases.

Indexed as

Disease ManagementOphthalmologistsRheumatologistsAutoimmune DiseasesEye DiseasesFemaleHumansImmunosuppression TherapyImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesImmunosuppressive Agentscorticosteroidsimmunosuppressionmultidisciplinaryscleritissystemic diseasestreatmentUveitis

Identifiers

PMID32749781
PMCPMC7984222
OpenAlexW3047271682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.